Trial Profile
A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of AMG 714 After Multiple Dose Administration in Subjects With Moderate to Severe Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2014
Price :
$35
*
At a glance
- Drugs Ordesekimab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Sponsors Amgen
- 17 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Oct 2009 New trial record